| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.19 | 8e-07 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-06 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.17 | 1e-06 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-06 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.18 | 8e-06 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.14 | 9e-06 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.14 | 1e-05 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.15 | 1e-05 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-05 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.24 | 2e-05 |